[vc_row css=”.vc_custom_1768333228562{background-color: #d4d4d4 !important;}”][vc_column][vc_single_image image=”9992″ img_size=”” alignment=”center” el_class=”banner-img”][/vc_column][/vc_row][vc_row][vc_column width=”2/3″][vc_column_text]
Craig Sale is a Professor of Human Physiology and Nutrition at Manchester Metropolitan University. His research has helped shape the global evidence base for beta-alanine supplementation. Widely published in sports nutrition and exercise science, his current work explores the translational potential of carnosine-related nutrition for healthy ageing and cardiometabolic health.
The Next Chapter for Beta-Alanine: Opportunities in Cardiometabolic Health and Disease
For more than two decades, beta-alanine (BA) has been recognized as a performance nutrition ingredient, supported by evidence demonstrating its ability to increase muscle carnosine content and enhance high-intensity exercise capacity. Preclinical and emerging human research suggests that the physiological relevance of BA and carnosine extends beyond sport performance. This presentation will explore the transition of BA from sport supplement to potential cardiometabolic health intervention. The evidence linking carnosine biology with key mechanisms implicated in obesity, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular dysfunction, including glycation stress, oxidative stress, inflammation, and mitochondrial impairment, will be reviewed. The talk will critically examine recent translational studies investigating BA’s potential to influence metabolic health outcomes across diverse populations. Some attention will be given to the rapidly changing therapeutic landscape shaped by incretin-based medications. While highly effective for weight loss, these treatments may be associated with reductions in lean mass and physical function. Professor Sale will consider whether BA supplementation, alongside exercise, could represent a complementary strategy to support muscle quality, physical capacity, and long-term cardiometabolic health in individuals using these therapies. Future research priorities will be discussed.
[/vc_column_text][/vc_column][vc_column width=”1/3″][vc_column_text]
06/14/2027 – 06/16/2027
Wyndham Grand Jupiter at Harbourside Place, Jupiter, Florida[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]
[/vc_column_text][/vc_column][/vc_row]
Give Your Brand the Edge with CarnoSyn® Brands
Add proven performance benefits to your product. Contact us below to find out more about CarnoSyn®, SR CarnoSyn®, CarnoSyn® 4X, and TriBsyn®.
Contact UsCarnoSyn® Brands eBook